Psyched Wellness Moves To Next Stage Of Pre-Clinical Trials With Mushroom Extract

Psyched Wellness (CSE: PSYC) continues to execute on its strategy as it pertains to the amanita muscaria mushroom. The company, through its contract research organization, KGK Science, has now begun the next pre-clinical trial study on its proprietary extract, referred to as AME-1.

The next round of pre-clinical trials focuses on the beneficial or adverse health extracts of the compound, with the trial referred to as a conditioned placement preference study. The study itself reportedly works by comparing characteristics of the association of the extract in an environment, to the association in another environment without the extract.

Effectively, the study will look into whether the compound developed by Psyched has any abuse potential. The trial is a means of determining whether psychological or physical dependence of the substance can be formed around the extract.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

“In conjunction with the other studies the Company is conducting, this trial will bolster Psyched’s toxicological assessment of AME-1 and provide critical knowledge of any behavioral and neurological functional changes in a scientific setting. This is another key step in determining a safe dose of AME-1 for human consumption and moves Psyched closer to being able to bring our Amanita-based CPG products to market,” commented David Shisel, COO of Psyched Wellness.

Psyched Wellness last traded at $0.135 on the CSE.


FULL DISCLOSURE: Psyched Wellness is a client of Canacom Group, the parent company of The Deep Dive. The author has been compensated to cover Psyched Wellness on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

Psychedelics: Sector Tailwinds To Come – The Daily Dive feat Psyched Wellness CEO Jeff Stevens

Starting off the short Canadian trading week this week on the Daily Dive is that...

Tuesday, May 25, 2021, 01:30:00 PM

Psyched Wellness: Canaccord Pens “Future In Fungi Report”

Yesterday morning, Canaccord Genuity released a primer into five psychedelic companies that they “believe could...

Tuesday, March 9, 2021, 11:49:00 AM

Psyched Wellness Completes 14 Day Oral Toxicity Preclinical Study For Proprietary Extract

Psyched Wellness (CSE: PSYC) this morning announced the results of its initial 14-day oral toxicity...

Tuesday, July 6, 2021, 08:58:10 AM

Psyched Wellness Raises $6.6 Million In Bought Deal Financing

Psyched Wellness (CSE: PSYC) has closed its previously announced private placement. The company managed to...

Wednesday, February 17, 2021, 11:38:02 AM

Psyched Wellness To Commence Trading Today

Psyched Wellness (CSE: PSYC) is the latest mushroom issue to hit the CSE, with the...

Thursday, October 22, 2020, 08:36:53 AM